IL10 and Splenomegaly: The IL-10−/− mice treated with exogenous WT BregIL-33, and to a less extent IL-10−/−BregIL-33, were clearly prevented from developing splenomegaly, a clinical condition usually caused by the inflammatory responses concomitant with IBD development.